Bisphenol A (BPA) is one of the most prevalent and best studied endocrine disruptors. After years of exposure to consumer products containing BPA, most individuals tested have circulating BPA at the low nanomolar levels. In addition to its well documented actions on the reproductive system, BPA exerts a wide variety of metabolic effects. This review summarizes recent findings on the ability of BPA, at environ mentally relevant doses, to inhibit adiponectin and stimulate the release of inflammatory adipokines such as interleukin-6 (IL-6) and tumor necrosis factor c (TNFc) from human adipose tissue. Expression of sev eral classical and non-classical estrogen receptors in human adipose tissue raises the possibility of their involvement as mediators of BPA actions. The implications of these observations to the obesity-related metabolic syndrome and its sequelae are discussed.
Being lipophilic, BPA also accumulates in human fat (Fernandez et al., 2007) . Bisphenol A diglycidyl ether (BADGE), is a component of epoxy resins (Fig. 1) . Workers who spray epoxy resins had higher urinary and plasma levels of both BADGE and BPA than controls, indicating that BPA can be endogenously generated from BADGE (Hanaoka et al., 2002) .
In 1993, Krishnan et al. discovered a substance that leached from polycarbonate flasks during autoclaving and acted like an estro gen by increasing the proliferation of breast cancer cells (Krishnan et al., 1993) . Using sequential chromatography they identified this compound as BPA. Soon thereafter, BPA was detected in food cans and dental cement (Brotons et al., 1995; Olea et al., 1996) . At about the same time, we were studying interactions between prolactin (PRL) and estradiol (E2). Upon noticing a striking structural simi larity between BPA and the potent estrogen diethylstilbestrol (DES) (Fig. 1) , we set out to examine if BPA altered PRL production. Our study (Steinmetz et al., 1997) was the first to show estrogen-like properties of BPA within the neuroendocrine axis in vitro and in vivo. This was followed by reporting on the effects of BPA on the reproductive tract in female rats , and the induction of prolonged hyperprolactinemia following treatment of neonatal rats with BPA (Khurana et al., 2000) . We also found exquisite sensitivity of some rat strains (i.e., Fischer 344) to the estrogen-mimetic effects of BPA (Long et al., 2000) .
A recent PubMed search revealed more than 2000 publications with a focus on BPA. Studies with rodents demonstrate that BPA elic its a wide range of activities, including neurochemical alterations, abnormalities in sperm and oocyte maturation, disruption of fer tility, changes in growth rates and immune dysfunctions (Richter et al., 2007) . This is supported by reports on the effects of BPA on proliferation, differentiation, ion transport, and hormone release in cultured cells (Wetherill et al., 2007) . BPA also has an ecological impact on wildlife (Crain et al., 2007) .
The growing interest by scientists and the public alike has placed BPA at the center of the debate over adverse effects of endocrine disruptors on fetal development, reproductive fecundity and carcinogenesis. Yet, attribution of such actions to BPA has been controversial. Indeed, differences of opinion and disagreements over data interpretation underlie the inability of several expert panels to reach binding decisions as to potential hazards of BPA to human health. A major issue, often raised by the chemical and food industries, is the micromolar doses of BPA used in many stud ies. Unless BPA is shown to be active at environmentally relevant concentrations (low nanomolar range), it is difficult to make a per suasive argument that BPA is hazardous to health. Another issue is a lack of linear dose-dependency of BPA effects, often showing a 'U' or an inverted 'U' shaped curves. Thus, extrapolation from action, or lack of action, of BPA at high doses to its presumed bioactivity at low doses is unwarranted.
The mechanism by which BPA exerts its actions is enigmatic. BPA and DES share structural features, and the estrogen receptor (ER) binds many dissimilar compounds. While BPA binds both ERc and ER� (Kuiper et al., 1998) , its binding affinity is ≈10,000-fold lower than that of E2, suggesting that it should mimic or com pete with estrogens only at the JM range. Yet, BPA at nanomolar concentrations often exhibits estrogen-like activities that are sim ilar to, or stronger than, E2. Several speculations have been put forward to reconcile this disparity. One, differences in binding to serum proteins, transport and metabolism, as compared to estro gens, account for the low dose effect of BPA in animal studies, especially during fetal development (Welshons et al., 2006) . Two, BPA binds differently within the ligand binding domain of ERs and recruits a different set of co-regulators (Safe et al., 2002) . Three, BPA elicits rapid responses via non-genomic mechanisms by activating membrane-anchored ERs , unidentified nonclassical membrane estrogen receptor (ncmER; (Alonso-Magdalena et al., 2005) , or G-protein-coupled receptor 30 (GPR30; (Filardo and Thomas, 2005) ). Four, BPA binds to estrogen related receptors (ERR), of which ERR" has high binding affinity to BPA (Takayanagi et al., 2006) .
Metabolic actions of BPA
Although the pancreatic islets and adipocytes are not considered classical targets of estrogen, both express functional ERs (Le May et al., 2006; Pedersen et al., 2001 ). Nadal and co-workers found that 1 nM doses of BPA, E2 and DES were equally potent in sup pressing calcium oscillations in glucagon-producing mouse islet cells (Alonso-Magdalena et al., 2005) . This rapid effect was medi ated by a G-protein-coupled receptor which they named ncmER. Mice treated with low doses of E2 or BPA showed rapid increases in insulin release and reduced plasma glucose; this effect was not blocked by pretreatment with the ER antagonist ICI182,780 (Alonso-Magdalena et al., 2006) . Prolonged treatment with BPA or E2 caused chronic hyperinsulinemia and induction of insulin resis tance, an effect which was blocked by ICI. The authors suggested that BPA mimics the actions of E2 on blood glucose homeostasis via two pathways: a rapid pathway involving ncmER and a prolonged pathway involving ER.
Studies on the impact of BPA on adipose tissue yielded con flicting and hard to interpret data, most likely due to the wide range of administered doses. BPA accumulation in rat adipose tis sue was low in one study (Shin et al., 2004) but high in another (Nunez et al., 2001) . When given to rats at high doses for 15 days, BPA caused a reduction in body weight and a lower feeding effi ciency (Nunez et al., 2001 ), while others found that feeding BPA to rats for three months did not alter body weight, fat depots or triglyceride levels (Seidlova-Wuttke et al., 2005) . Using 3T3-F442A adipocytes, Sakurai et al. (2004) reported that BPA stimulated insulin-dependent glucose uptake and increased Glut4 expression; E2 was ineffective and ICI did not antagonize BPA. However, only the highest dose of BPA tested (100 JM) was effective. Others (Masuno et al., 2002 (Masuno et al., , 2005 reported that BPA accelerated adipogenesis in 3T3-L1 adipocytes. Again, BPA was active only at doses of 80 JM and above.
Until recently, there has been no information on BPA effects on human adipocytes. Using breast, subcutaneous and visceral adi pose tissue explants as well as isolated mature adipocytes from over 20 patients, we reported that BPA at 1 and 10 nM concen trations inhibits adiponectin release . Both BPA and E2 showed a clear 'U' shaped dose-response curve. We subse quently found that BPA stimulated the release of two inflammatory cytokines, IL-6 and TNFc. Unexpectedly, ICI mimicked, rather than antagonized, the effects of both BPA and E2 on the release of all three adipokines (Fig. 2) . To underscore the relevance of these findings to the metabolic syndrome and its sequelae, we discuss the key role of adiponectin as an insulin sensitizer, summarize salient features of IL-6 and TNFc as inflammatory adipocytokines, and speculate on the mechanisms by which BPA affects their release.
Adipose tissue and the metabolic syndrome
Human fat is distributed in discrete visceral and subcutaneous depots which differ in morphology and function (Wajchenberg et al., 2002) . Visceral fat comprises 6% of total body fat in women but 20% in men, reflecting the greater propensity of men to accumulate excess abdominal fat. Adipose tissue is composed of many cell types embedded in connective tissue matrix (Ailhaud et al., 1992) . The major cell type is the very large, terminally differentiated adipocyte, with a small number of proliferation-competent preadipocytes. The latter are fibroblast-like cells that are committed to the adipocyte lineage. The stromal fraction also contains endothelial and mast cells, fibroblasts and infiltrating macrophages (Rink et al., 1996) . Obesity results from increased adipocyte size (hypertrophy) and number (hyperplasia). Mature adipocytes carry out the bulk of adi pose tissue functions, given their ability to metabolize glucose, store and release free fatty acids, and secrete adipokines. Stromal macrophages contribute to the overall metabolic activity of adipose tissue by releasing adipocytokines such as TNFc and IL-6.
Increased abdominal visceral fat is a critical factor in the development and manifestation of the metabolic syndrome. This syndrome is defined by glucose intolerance, hyperinsulinemia, hypertriglyceremia, altered lipoprotein levels and hypertension (Ritchie and Connell, 2007) . Visceral fat is more sensitive to -adrenergic agonists and less responsive to insulin and c2-adrenergic agents than subcutaneous fat, making it more lipoly tically active (Arner, 2001) . Since the output of visceral fat drains into the hepatic portal blood, an increased influx of free fatty acids leads to inhibition of insulin clearance by the liver, thus contribut ing to hyperinsulinemia. Chronic elevation of free fatty acids also impairs glucose metabolism and insulin sensitivity in both the liver and muscle and reduces pancreatic cell function (Lewis et al., 2002) . There are significant differences between fat depots in the secretion of adipokines, with visceral fat secreting more IL-6 but less leptin and adiponectin than subcutaneous fat (Arner, 2001 ).
Adiponectin
Adiponectin is a 30 kDa adipocyte-specific hormone which forms several multimers: high molecular weight, low molecu lar weight and trimeric complexes (Trujillo and Scherer, 2005) . These circulate at ≈10 Jg/ml, comprising as much as 0.01% of total serum proteins in humans. The biological effects of adiponectin depend upon distinct properties of the multimers and tissuespecific expression of two receptors: skeletal AdipoR1 and hepatic AdipoR2 (Kadowaki and Yamauchi, 2005) . Adiponectin increases fatty acid oxidation and glucose metabolism in muscle, and reduces glucose output and enhances insulin sensitivity in liver. It also has anti-inflammatory and anti-atherogenic actions (Kadowaki et al., 2006) . Serum adiponectin levels are reduced before the develop ment of type 2 diabetes, are paradoxically lower in obese than in lean subjects, and increase after weight loss (Trujillo and Scherer, 2005) . Thus, adiponectin is considered a key regulator of insulin sensitivity and tissue inflammation. Consequently, any factor which suppresses adiponectin release could promote insulin resistance and increase the risk of developing the metabolic syndrome.
Adiponectin availability is controlled at three levels: biosynthe sis, assembly and release (Trujillo and Scherer, 2005) . Synthesis is stimulated by PPAR" agonists, insulin and IGF-1 and inhibited by TNFc and catecholamines (Lihn et al., 2005) . Increased adiponectin expression by PPAR" is of special interest since one mechanism by which BPA could suppress adiponectin is by antagonizing PPAR". Indeed, BADGE, the ether conjugated BPA (Fig. 1) , is a potent antag onist of PPAR" actions in adipocytes (Knouff and Auwerx, 2004; Wright et al., 2000) . Correct formation of disulfide bonds is crit ical for the assembly and retention of adiponectin (Trujillo and Scherer, 2005) . Disulfide bond formation within the endoplasmic reticulum is catalyzed by oxyreductases, of which protein disulfide isomerase (PDI) is a critical player (Tsao et al., 2003; Wang et al., 2007) . Since BPA was reported to bind PDI and inhibit its enzymatic activity (Hiroi et al., 2006) , this could represent another mechanism by which BPA suppresses adiponectin.
The control of adiponectin release is poorly understood. Unlike most neuroendocrine cells, adipocytes do not have high storage capacity secretory granules and lack calcium-dependent exocy tosis (Mora and Pessin, 2002) . Thus, the secretory pathway of adipokines is often referred to as 'constitutive'. Although adipocytes have Glut4-containing vesicles which rapidly translocate to the cell membrane in response to insulin, these vesicles do not con tain adiponectin (Bogan and Lodish, 1999) . This raises the question of whether adipocytes can regulate the release of adipokines once they are synthesized. Scherer and co-workers (Wang et al., 2007) reported that both assembly and release of adiponectin depend upon thiol-mediated retention within the endoplasmic reticulum. This process involves reciprocal interactions between PDI and sev eral chaperones. This concept stipulates that a large proportion of de novo synthesized adiponectin is not immediately secreted but is retained within the endoplasmic reticulum. Such a pool is regulat able by compounds that modify disulfide bond formation or alter chaperone functions.
IL-6 and TNFa
IL-6 is a pleiotropic cytokine made of a single chain of 185 amino acids which configures as two pairs of anti-parallel c-helices (Kamimura et al., 2003) . Binding of IL-6 to the IL-6Rc receptor recruits gp130, a non-ligand binding protein. The activated receptor
complex induces phosphorylation of Jak kinases, followed by acti vation of STAT3 and MAP kinase. In addition to most immune cells, IL-6 is produced by preadipocytes, adipocytes, and macrophages residing within adipose tissue. IL-6 is intimately involved with inflammatory states, hematopoiesis, immune responses and host defense mechanism (Heinrich et al., 2003) . Within adipose tissue, IL-6 stimulates lipolysis, inhibits lipopro tein lipase activity, antagonizes insulin-stimulated glucose uptake and suppresses adiponectin release (Kamimura et al., 2003) . Elevated serum IL-6 levels are associated with increased cardio vascular risk in obese and diabetic patients and contribute to the low grade inflammation that accompanies the metabolic syndrome (Spranger et al., 2003) . IL-6 expression in adipocytes is stimulated by insulin, TNFc, and -adrenergic agonists, and is inhibited by glucocorticoids (Hoene and Weigert, 2008) . We recently reported that IL-6 gene expression and release in human preadipocytes are differentially regulated . Whereas insulinstimulated IL-6 expression is mediated by the cGMP/PKG/CREB pathway, insulin-induced IL-6 release also requires MAPK signal ing. The pathway by which BPA increases IL-6 release remains to be determined.
TNFc is the most potent and best studied inflammatory cytokine (Qi and Pekala, 2000; Ryden and Arner, 2007) . It is initially pro duced as a membrane-associated monomer which is proteolytically cleaved and circulates as a homotrimer. TNFc produced by human adipose tissue does not appear to be cleaved, but remains near the producing cells and acts as an autocrine/ paracrine factor (Mohamed-Ali et al., 1997). TNFc binds to two receptors, TNFR1 and TNFR2, which can form multimeric complexes upon ligand bind ing. TNFR1 is an important member of the death receptor family characterize by an intracellular death domain and the induction of apoptosis upon activation. Recruitment of adaptor proteins that bind to the death domain activates a signaling cascade. A recent model suggests that occupation of TNFR1 activates two opposing pathways: one leads to apoptosis and the other, via the NF-KB path way, protects against it. The fate of a cell depends on which pathway predominates (Qi and Pekala, 2000) .
There is a strong correlation between increased TNFc produc tion, adiposity and insulin resistance (Ryden and Arner, 2007) . TNFc affects insulin resistance by downregulating the glucose transporter, interfering with insulin receptor phosphorylation and signaling, and by inhibiting transcription factors that affect insulin sensitivity. It also stimulates lipolysis, leading to increased free fatty acids and a further suppression of insulin sensitiv ity. Although increased TNFc production in obesity, primarily by infiltrating macrophages (Fain et al., 2004) , has been exten sively studied, less is known about the hormonal regulation of its release.
Estrogen receptors in human adipose tissue
The unmistakable difference in the anatomical distribution of fat between men and women raises the prospect that gonadal steroids affect the development or metabolism of adipose tissue. Both ERc and ER are expressed in human fat in a depot-specific manner (Dieudonne et al., 2004; Pedersen et al., 2001) . Although serum adiponectin levels are moderately higher in women than men, hor mone replacement therapy does not affect adiponectin release in either pre-or post-menopausal women (Sieminska et al., 2005) . Thus, the gender difference in adiponectin appears to be due to a suppressive effect by androgens in men rather than to a direct stim ulation by estrogens (Andersen et al., 2007) . There is no evidence for gender differences in circulating IL-6 or TNFc levels in humans (Asai et al., 2001) .
The equipotency of BPA and E2 in suppressing adiponectin and stimulating IL-6 and TNFc release (Fig. 2) suggests involvement of receptors other than classical ERs. This is supported by the mim icking, rather than antagonizing, actions of ICI. Although BPA has a higher binding affinity to ER than ERc (Kuiper et al., 1998) , it is still at a JM range, compared to a low nM for E2. The binding affinity of BPA to GPR30 is 630 nM (Thomas and Dong, 2006) , and 9 nM for ERR" (Okada et al., 2008) . To compare expression of these receptors in human visceral adipose tissue, we used real-time PCR. Fig. 3 shows that relative to ERc, expression of ER is quite signifi cant. Of the ERR family members, ERR" has the highest expression, approaching 25% of ERc mRNA levels. In contrast, expression of GPR30 was very low.
Most research to-date on the biological actions of estrogens has focused on ERc. Studies with knockout mice revealed that deletion of ERc causes a much more severe phenotype than deletion of ER (Couse and Korach, 1999) . With the exception of a few tissues such as the ovary, prostate and certain areas of the brain, ERc is more highly expressed than ER . Therefore, it was unexpected to find similar mRNA levels of both receptors in human visceral fat (Fig. 3) . This is in contrast to a previous report on the predominance of ERc over ER in isolated mature adipocytes (Dieudonne et al., 2004) . Given adipose tissue heterogeneity, it is difficult to compare recep tor expression in whole tissue, as was done in our studies, with that in isolated adipocytes. In addition, at least four different ER sub types are expressed in human adipose tissue (Pedersen et al., 2001) , with our primers detecting only the common isoform. As reported by us recently , and depicted in Fig. 3 , this is the first demonstration of GPR30 and ERR" expression in human fat.
GPR30 is a seven-transmembrane receptor which activates sec ond messengers such as adenylate cyclase and MAP kinase in response to E2 (Filardo and Thomas, 2005) . Notably, ICI acts as a GPR30 agonist, similar to its action on adipokine release (Fig. 2) . In spite of the low expression of GPR30 in visceral fat (Fig. 3) , medi ation of BPA actions by this receptor should not be ruled out. An especially attractive candidate is ERR". The ERRs are orphan nuclear receptors which are constitutively active and do not bind estrogens (Ariazi and Jordan, 2006) . ERR" is expressed in a tissue-specific manner (Heard et al., 2000) , but little is known about its biologi cal functions. Future studies should first confirm expression of all the above receptors in human fat at the protein level, and then use siRNA to determine the consequences of receptor knockdown on the ability of E2 or BPA to alter adipokine release. It would also be of interest to determine whether BPA at low doses affects other func tions of human adipocytes such as adipogenesis, glucose transport and lipid metabolism. Adiponectin is an insulin sensitizer whereas cytokines such as IL-6 and TNFc pro mote insulin resistance. The opposing actions of BPA on these adipokines contribute to the development and manifestation of the metabolic syndrome.
Conclusions and perspectives
To firmly establish the metabolic effects of BPA, it is criti cally important to recognize the full spectrum of its actions on human fat. Although the value of rodents and murine adipocytes as experimental models is undisputed, there are sufficient dif ferences in adipocyte biology between rodents and humans to warrant prudence . For example, the regional distribution of fat depots, their cellular composition (e.g., brown vs white fat, infiltration by macrophages), and the regula tion of resistin, agouti protein, adipsin, and adrenergic receptors are dissimilar in rodents and humans. Interspecies differences in the cellular milieu are highlighted by the dependence on serum for adipogenesis in 3T3-L1 cells, while human preadipocytes undergo differentiation without serum (Hauner et al., 2000) . Intrinsic differ ences between the species are also exemplified by the suppression of adiponectin expression in 3T3-L1 cells by insulin but its induction by insulin in human adipose tissue (Whitehead et al., 2006) .
Most attention to-date has focused on high caloric food intake and sedentary life style as the root causes of the obesity epidemic. However, the roles of genetic predisposition and environmental fac tors should not be ignored. Lower circulating adiponectin levels and elevated inflammatory cytokines are strongly associated with increased risks of obesity-related diseases. Given its prevalence in the environment, presence in serum from humans worldwide, sup pression of adiponectin and increased IL-6 and TNFc release at nanomolar concentrations, BPA may be the bona fide endocrine dis ruptor that adversely affects metabolic homeostasis. Fig. 4 presents a model which incorporates input by environmental factors to the combined effects of diet, exercise and genetics on the development and manifestation of the metabolic syndrome.
